Fate Therapeutics (FATE) Free Cash Flow (2012 - 2026)
Fate Therapeutics (FATE) posted Free Cash Flow of -$31.1 million for Q1 2026, down 7.59% on a QoQ basis from -$28.9 million in Q4 2025, and up 9.87% year-over-year from -$28.3 million in Q1 2025.
Fate Therapeutics (FATE) Free Cash Flow (2012 - 2026) Analysis & Trends
Fate Therapeutics' Free Cash Flow history runs 15 years deep, the most recent figure standing at -$31.1 million for Q1 2026.
- Quarterly Free Cash Flow rose 9.87% year-over-year to -$31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.6 million (up 12.47% YoY) and the FY2025 annual result came in at -$112.0 million, up 8.92% from the prior year.
- Free Cash Flow was -$31.1 million for Q1 2026 at Fate Therapeutics, down from -$28.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$23.8 million in Q3 2025 and bottomed at -$70.0 million in Q2 2022.
- A 5-year average of -$38.5 million and a median of -$32.4 million in 2024 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 59.48% in 2022, while the deepest fall reached 228.52% in 2022.
- Fate Therapeutics' Free Cash Flow stood at -$47.6 million in 2022, then grew by 10.37% to -$42.6 million in 2023, then jumped by 34.49% to -$27.9 million in 2024, then decreased by 3.39% to -$28.9 million in 2025, then declined by 7.59% to -$31.1 million in 2026.
- Business Quant data shows FATE's Free Cash Flow at -$31.1 million in Q1 2026, -$28.9 million in Q4 2025, and -$23.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | -31.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.06 Mn |
| Mar 31, 2026 | -31.06 Mn |
| Dec 31, 2025 | -28.87 Mn |
| Dec 31, 2025 | -28.87 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Jun 30, 2025 | -24.93 Mn |
| Jun 30, 2025 | -24.93 Mn |
| Mar 31, 2025 | -34.46 Mn |
| Mar 31, 2025 | -34.46 Mn |
| Dec 31, 2024 | -27.92 Mn |
| Dec 31, 2024 | -27.92 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Jun 30, 2024 | -32.43 Mn |
| Jun 30, 2024 | -32.43 Mn |
| Mar 31, 2024 | -33.36 Mn |
| Mar 31, 2024 | -33.36 Mn |
| Dec 31, 2023 | -42.62 Mn |
| Dec 31, 2023 | -42.62 Mn |